HIV/AIDS Treatment
Metabolic abnormalities less with atazanavir than with other protease inhibitors
Published in AIDS Weekly, February 28th, 2005
"Atazanavir is the first once-daily protease inhibitor for the treatment of HIV-1 infection and should be used only in combination therapy, as part of a highly active antiretroviral therapy (HAART) regimen.
"In addition to being the most potent protease inhibitor in vitro, atazanavir has a distinct cross-resistance profile that does not confer resistance to other protease inhibitors. However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir," researchers in the United States report.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-02-28)
More Articles from AIDS Weekly
- HIV/AIDS Drug Monitoring
Genotypic inhibitory quotient predictive of virological response to SQV/RTV - HIV/AIDS Research
HIV-1-RT Gln145Met/leu change confer drug resistance/impair virus replication - HIV/AIDS Therapy
New findings in the area of HIV/AIDS therapy described - HIV/AIDS Transmission
Coreceptor-independent HIV transfer induced by contacts between CD4 cells - HIV/AIDS-Related Tuberculosis
AIDS-related mycobacterial reactivation may result from T-cell immunity loss - Amyotrophic Lateral Sclerosis
Research finds new evidence of retroviral involvement in brain disease - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
